Table 2.
Clearance subgroups.
| Clearance subgroups | HR-HPV clearance | HR-HPV clearance |
|---|---|---|
| T1 (6 months) | T2 (12 months) | |
| Overall clearance | ||
| Cases | 96/136 (70.5%) | 114/136 (83.8%) |
| HPV clearance genotype | ||
| 16 (56 pts) | 51/56 (91.1%) | 54/56 (96.4%) |
| 53 (19 pts) | 16/19 (84.2%) | 17/19 (89.5%) |
| 18 (16 pts) | 11/16 (69%) | 14/16 (87.5%) |
| 31 (15 pts) | 10/15 (66%) | 13/15 (86.6%) |
| Others (10 pts) | 6/10 (60%) | 9/10 (90%) |
| Coinfected (20 pts) | 2/20 (1%) | 7/20 (3.5%) |
| Total (136 pts) | 96/136 (70.5%) | 114/136 (83.8%) |
| Smoking patients | ||
| Smoking patients group (39 pts) | 26/39 (66.7%) | 28/39 (71.8%) |
| No-smoking patients group (97 pts) | 70/97 (72.2%) | 85/97 (87.6%) |
| COC users | ||
| COC users group (46 pts) | 28/46 (60.9%) | 69.5% (32/46) |
| COC non-users group (91 pts) | 64/91 (70.3%) | 87.9% (80/91) |
| Stratified by age | ||
| <25 (10 pts) | 9/10 (90 %) | 10/10 (100 %) |
| 25–30 (19 pts) | 14/19 (73.6%) | 17/19 (89.4 %) |
| 30–35 (18 pts) | 14/18 (77.8 %) | 17/18 (94.4%) |
| 35–40 (25 pts) | 15/25 (60 %) | 23/25 (92%) |
| >40 (64 pts) | 44/64 (73.3 %) | 57/64 (89.1%) |
| Total | 96/136 | 114/136 |
Pts, patients; COC, Combined oral contraceptive.